The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer ...

Daiichi Sankyo and AstraZeneca’s Enhertu has been recommended for approval in the European Union as a monotherapy for the treatment of adult patients with unresectable or metast ...

AstraZeneca (AZN) and Daiichi Sankyo’s (DSNKY) trastuzumab deruxtecan has been recommended for approval in the European Union as a monotherapy ...

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo said on Friday that the European Medicines Agency (EMA) endorsed ENHERTU for the ...

(Alliance News) - AstraZeneca PLC on Friday said its breast cancer therapy, Enhertu, which is being developed jointly with Tokyo-based pharmaceutical company Daiichi Sankyo Co Ltd, has been ...

The U.S. Centers for Disease Control and Prevention upheld the role of vaccines in offering protection against measles after ...

Affirm Holdings, Inc. , the payment network that empowers consumers and helps merchants drive growth, today announced that Rob O'Hare, CFO of Affirm, will participate in a fireside chat to answer a ...

Certified Partner under the CAPiCO Certified Partner program, a program just launched in February 2025 by YRGLM Inc. (Headquarters: Osaka, Japan; Chief Executive Officer: ...

Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc., JD.com, and AstraZeneca are the five Pharmaceutical stocks to watch today, according to MarketBeat’s stock screener tool. Pharmaceutical ...

Approval would expand the use of Enhertu to breast cancer patients with nearly undetectable HER2 levels in their tumors.

Researchers have made a significant breakthrough in cancer drug discovery by identifying a new binding site on the eukaryotic initiation factor 4 ...